LMAT - Public offerings

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of peripheral vascular devices, implants and services, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $54.50 per share. Gross proceeds to LeMaitre from the offering are expected to be approximately $54.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by LeMaitre. The offering is expected to close on or about July 16, 2021, subject to customary closing conditions. LeMaitre has granted the underwriters of the offering the right for a period of 30 day

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of peripheral vascular devices, implants and services, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by LeMaitre. In addition, LeMaitre intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual s

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of peripheral vascular devices, implants and services, today announced preliminary unaudited results for the quarter ended June 30, 2021. Q2 2021 Preliminary Results Net Sales of $40.7mm, +64% reported, +35% organic vs. Q2 2020Gross Margin of 65.5% to 66.1%, -2.7% at the midpoint vs. Q2 2020Operating Income of approximately $10.9mm to $11.3mm, +128% at the midpoint vs. Q2 2020Cash and Cash Equivalents of $21.8 millionDebt paid down $9mm to $23.0mm By product, Q2 sales growth was driven by Artegraft (acquired in June 2020) with sales of $6.7 million, as well as by valvulotomes, shunts a